Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio de talquetamab con otras terapias contra el cáncer en participantes con mieloma múltiple (MonumenTAL-2)

2 de noviembre de 2026 actualizado por: Janssen Research & Development, LLC

Un estudio de fase 1b de múltiples brazos de talquetamab con otras terapias contra el cáncer en participantes con mieloma múltiple

The purpose of this study is to characterize the safety and tolerability of talquetamab when administered in different combination regimens and to identify the safe dose(s) of talquetamab combination regimens.

Descripción general del estudio

Estado

Activo, no reclutando

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Actual)

166

Fase

  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Fitzroy, Australia, 3065
        • St Vincents Hospital Melbourne
      • Melbourne, Australia, 3004
        • Alfred Health
      • Southport, Australia, 4215
        • Gold Coast University Hospital
      • Wollongong, Australia, 2500
        • Wollongong Hospital
      • Brussels, Bélgica, 1200
        • Cliniques Universitaires St-Luc
      • Edegem, Bélgica, 2650
        • UZA
      • Ghent, Bélgica, 9000
        • UZ Gent
      • Leuven, Bélgica, 3000
        • UZ Leuven
    • Alabama
      • Birmingham, Alabama, Estados Unidos, 35294
        • University of Alabama Birmingham
    • California
      • San Francisco, California, Estados Unidos, 94143
        • University of California San Francisco
    • Colorado
      • Denver, Colorado, Estados Unidos, 80218
        • Colorado Blood Cancer Institute
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30322
        • Emory University
    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46202
        • Indiana University
    • New Jersey
      • Hackensack, New Jersey, Estados Unidos, 07601
        • Hackensack University Medical Center
    • New York
      • New York, New York, Estados Unidos, 10065
        • Weill Cornell Medical College
      • New York, New York, Estados Unidos, 10029
        • Mt. Sinai School of Medicine
    • North Carolina
      • Charlotte, North Carolina, Estados Unidos, 28204
        • Levine Cancer Institute
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Estados Unidos, 15232
        • University of Pittsburgh Medical Center
    • Tennessee
      • Nashville, Tennessee, Estados Unidos, 37203
        • Tennessee Oncology
    • Wisconsin
      • Milwaukee, Wisconsin, Estados Unidos, 53226
        • Medical College Of Wisconsin
      • Nantes, Francia, 44093
        • CHU Nantes
      • Pessac, Francia, 33604
        • CHU de Bordeaux - Hospital Haut-Leveque
      • Rennes, Francia, 35000
        • Chu Rennes Hopital Pontchaillou
      • Toulouse, Francia, 31059
        • Institut Universitaire du cancer de Toulouse-Oncopole
      • Groningen, Países Bajos, 9713 GZ
        • UMCG
      • Maastricht, Países Bajos, 6229 HX
        • Maastricht University Medical Centre
      • Utrecht, Países Bajos, 3584 CX
        • UMCU
      • London, Reino Unido, W1T 7HA
        • University College Hospital London
      • Manchester, Reino Unido, M20 4BX
        • The Christie Nhs Foundation Trust
      • Oxford, Reino Unido, OX3 7LE
        • Churchill Hospital
      • Surrey, Reino Unido, SM2 5PT
        • The Royal Marsden NHS Trust Sutton

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Have documented initial diagnosis of multiple myeloma according to International Myeloma Working Group (IMWG) diagnostic criteria
  • Have measurable disease at screening as defined by at least 1 of the following: a. Serum monoclonal protein (M-protein) level greater than or equal to (>=) 1.0 gram per deciliter (g/dL); or b. Urine M-protein level >= 200 milligrams (mg)/24 hours; or c. Light chain multiple myeloma: Serum immunoglobulin (Ig) free light chain (FLC) >=10 milligrams per deciliter (mg/dL) and abnormal serum Ig kappa lambda FLC ratio
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 at screening and immediately before the start of study treatment administration
  • A woman of childbearing potential must have a negative highly sensitive serum beta human chorionic gonadotropin (beta-hCG) pregnancy test at screening and a negative urine or serum pregnancy test within 24 hours before the start of study treatment administration
  • Be willing and able to adhere to the lifestyle restrictions specified in the protocol, including adherence to the applicable immunomodulatory drug (IMiD) global Pregnancy Prevention Plan (PPP) or local PPP/Risk Evaluation and Mitigation Strategy (REMS) program

Exclusion Criteria:

  • Live, attenuated vaccine within 4 weeks before the first dose of study treatment
  • Received a cumulative dose of corticosteroids equivalent to >=140 mg of prednisone within the 14-day period before the start of study treatment administration
  • Active central nervous system (CNS) involvement or exhibition of clinical signs of meningeal involvement of multiple myeloma. If either is suspected, brain magnetic resonance imaging (MRI) and lumbar cytology are required
  • Known to be seropositive for human immunodeficiency virus
  • History of stroke or seizure within 6 months prior to the first dose of study treatment

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Treatment Regimen A: Talquetamab + Carfilzomib

Participants assigned to Treatment regimen A will receive talquetamab subcutaneously (SC) in combination with carfilzomib as an intravenous (IV) infusion.

Talquetamab will be administered subcutaneously.

Otros nombres:
  • JNJ-64407564

Carfilzomib will be administered as an IV infusion.

Experimental: Treatment Regimen B: Talquetamab + Daratumumab + Carfilzomib

Participants assigned to Treatment regimen B will receive talquetamab SC in combination with daratumumab SC and carfilzomib as an IV infusion.

Talquetamab will be administered subcutaneously.

Otros nombres:
  • JNJ-64407564

Carfilzomib will be administered as an IV infusion.

Daratumumab will be administered subcutaneously.

Experimental: Treatment Regimen C: Talquetamab + Lenalidomide

Participants assigned to Treatment regimen C will receive talquetamab SC in combination with lenalidomide orally.

Talquetamab will be administered subcutaneously.

Otros nombres:
  • JNJ-64407564

Lenalidomide will be self-administered orally.

Experimental: Treatment Regimen D: Talquetamab + Daratumumab + Lenalidomide

Participants assigned to Treatment regimen D will receive talquetamab SC in combination with daratumumab SC and lenalidomide orally.

Talquetamab will be administered subcutaneously.

Otros nombres:
  • JNJ-64407564

Daratumumab will be administered subcutaneously.

Lenalidomide will be self-administered orally.

Experimental: Treatment Regimen E: Talquetamab + Pomalidomide

Participants assigned to Treatment regimen E will receive talquetamab SC in combination with pomalidomide orally.

Talquetamab will be administered subcutaneously.

Otros nombres:
  • JNJ-64407564

Pomalidomide will be self-administered orally.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability
Periodo de tiempo: Up to 1 year and 10 months

An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.

Up to 1 year and 10 months
Number of Participants with AEs by Severity
Periodo de tiempo: Up to 1 year and 10 months

Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening, and Grade 5= Death related to AE.

Up to 1 year and 10 months
Number of Participants with Clinically Significant Abnormalities in Laboratory Parameters
Periodo de tiempo: Up to 1 year and 6 months

Number of participants with clinically significant abnormalities in laboratory parameters such as hematology and serum chemistry will be reported.

Up to 1 year and 6 months
Number of Participants with Dose Limiting Toxicity (DLT)
Periodo de tiempo: Up to 49 days

Number of participants with DLT will be reported. The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity of grade 3 or higher, clinical laboratory abnormalities, or hematologic toxicity.

Up to 49 days

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Overall Response Rate (ORR)
Periodo de tiempo: Up to 1 year and 10 months

ORR is defined as the percentage of participants who achieve partial response (PR) or better according to the International Myeloma Working Group (IMWG) 2016 criteria. Response to treatment will be evaluated by the investigator based on IMWG criteria.

Up to 1 year and 10 months
Very Good Partial Response (VGPR) or Better Response Rate
Periodo de tiempo: Up to 1 year and 10 months

VGPR or better response rate is defined as the percentage of participants who achieve a VGPR or better response (stringent complete response [sCR] + complete response [CR] +VGPR) according to the IMWG 2016 criteria.

Up to 1 year and 10 months
Complete Response (CR) or Better Response Rate
Periodo de tiempo: Up to 1 year and 10 months

CR or better response rate is defined as the percentage of participants who achieve a CR or better response (sCR+CR) according to the IMWG 2016 criteria.

Up to 1 year and 10 months
Stringent Complete Response (sCR)
Periodo de tiempo: Up to 1 year and 10 months

sCR rate is defined as the percentage of participants who achieve an sCR according to the IMWG 2016 criteria.

Up to 1 year and 10 months
Duration of Response
Periodo de tiempo: Up to 1 year and 10 months

Duration of response is defined as time from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the IMWG 2016 criteria, or death due to disease progression, whichever occurs first.

Up to 1 year and 10 months
Time to Response
Periodo de tiempo: Up to 1 year and 10 months

Time to response is defined as the time between date of first dose of study treatment and the first efficacy evaluation at which the participant has met all criteria for PR or better.

Up to 1 year and 10 months
Serum Concentration of Talquetamab
Periodo de tiempo: Up to 1 year and 10 months

Serum samples will be analyzed to determine concentrations of talquetamab.

Up to 1 year and 10 months
Serum Concentration of Daratumumab
Periodo de tiempo: Up to 1 year and 10 months

Serum samples will be analyzed to determine concentrations of daratumumab for treatment regimens B and D.

Up to 1 year and 10 months
Number of Participants with Anti-Drug Antibodies to Talquetamab
Periodo de tiempo: Up to 1 year and 10 months

Number of participants with anti-drug antibodies to talquetamab will be reported.

Up to 1 year and 10 months
Number of Participants with Anti-Drug Antibodies to Daratumumab
Periodo de tiempo: Up to 1 year and 10 months

Number of participants with anti-drug antibodies to daratumumab will be reported for treatment regimens B and D.

Up to 1 year and 10 months
Number of Participants with Anti-Drug Antibodies to Recombinant Human Hyaluronidase PH20 Enzyme (rHuPH20)
Periodo de tiempo: Up to 1 year and 10 months

Number of participants with anti-drug antibodies to rHuPH20 will be reported.

Up to 1 year and 10 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Director de estudio: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

22 de septiembre de 2021

Finalización primaria (Actual)

31 de marzo de 2025

Finalización del estudio (Estimado)

31 de diciembre de 2027

Fechas de registro del estudio

Enviado por primera vez

10 de septiembre de 2021

Primero enviado que cumplió con los criterios de control de calidad

10 de septiembre de 2021

Publicado por primera vez (Actual)

20 de septiembre de 2021

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

3 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

2 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • CR108946
  • 2020-004502-55 (Número EudraCT)
  • 64407564MMY1004 (Otro identificador: Janssen Research & Development, LLC)
  • 2023-503620-60-00 (Identificador de registro: EUCT number)
  • 2023 (Subvención/contrato del NIH de EE. UU.)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical-trials/transparency.

As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .